Shots:

• The approval is based on P-III UPTRAVI IV study evaluating the safety- tolerability- and PK of temporarily switching Uptravi (PO) to Uptravi (IV) in 20 patients with PAH
• The results showed that switching b/w Uptravi (PO) to Uptravi IV was well tolerated with no unexpected safety findings. Both formulations maintain the treatment effect for short-term temporary interruptions- AEs from Uptravi IV were similar to those associated with Uptravi tablets
• Uptravi is a selective- prostacyclin IP receptor agonist- approved for IV use for PAH- WHO Group I in the adult with WHO (FC) II–III- who are temporarily unable to take oral therapy

­ Ref: Janssen | Image: Janssen